CDSCO panel gives nod to Takeda Pharma for Vadolizumab

It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease

128
CDSCO DCGI FDA

Last Updated on January 4, 2022 by The Health Master

New Delhi: Takeda Pharmaceuticals has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) for marketing the gastrointestinal drug, Vedolizumab with additional strength thru the subcutaneous route.

This came in line with the proposal presented by Takeda Pharmaceuticals for the import and marketing of additional strength and a new route of administration of Vedolizumab.

Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation.

It is used in the treatment of moderate to severe active ulcerative colitis and Crohn’s disease for patients who have had an inadequate response to, lost response to, or are intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies. By blocking its primary target, α4β7 integrin, vedolizumab reduces inflammation in the gut.

Kynteles is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn’s Disease (CD). Vedolizumab is a gut-selective biologic and is approved as an intravenous formulation.

At the recent SEC meeting for Gastroenterology & Hepatology held on 17.12.2021, the committee extensively evaluated the drug maker Takeda Pharmaceuticals‘ proposal for the import and marketing of additional strength and a new route of administration of Vedolizumab.

The committee noted that Vedolizumab through the IV route is already approved for marketing in the country. Furthermore, the proposed additional strength through the subcutaneous route has been approved in the EU, Switzerland, etc.

After detailed deliberation, the committee recommended the grant of marketing permission for Vedolizumab of additional strength thru the subcutaneous route.

Further, the committee directed that the indication should reflect that the additional strength is for the subcutaneous route and only for maintenance purposes.

CDSCO approves Corbevax, Covovax and Molnupiravir for restricted use

DCGI gives nod to Serum India for developing jab against Omicron

DCGI gives approval to Biological E for Corbevax

DCGI gives nod to Sun Pharma arm for Molnupiravir in India

Covaxin gets emergency use approval from DCGI for children above 12 years

DCGI seeks more data from Serum Institute for Covovax Vaccine

These 13 Pharma Companies to launch Anti-COVID Drug Molnupiravir

DCGI gives nod to Serum India for developing jab against Omicron

Common ET Plant to help pharma firms to treat or reuse…

Pharma Firm booked for Rs 1,627 Crore Loan Fraud

Drug industry cheers FSSAI’s removal of ban on Methylcobalamin

USFDA gives tentative nod to Zydus Cadila for Pimavanserin capsules

Molnupiravir: A wonder drug or a limited star?

NPPA fixes retail price of 2 formulations: December 2021

NPPA fixes retail price of 28 formulations: December 2021

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner